Drug Trial Radar · NCT05052567
CEND-1 Injection (QLC12102) in Patients With Advanced Metastatic Pancreatic Ductal Adenocarcinoma
Last checked: Nov 19, 2026Latest source record: Sep 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
50
Actual
Start
Oct 21, 2021
Primary completion
Jun 29, 2024
Study completion Jun 29, 2024
Sponsor
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Cend Therapeutics Inc.
- First posted
- Sep 22, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to evaluate the preliminary safety, efficacy and PK characteristics of cend-1 in patients with advanced metastatic pancreatic ductal adenocarcinoma (Chinese population).
Conditions
- Pancreatic Cancer
Interventions
CEND-1Drug
The dose is specified according to the protocol. CEND-1+paclitaxel (albumin-bound type)+gemcitabine
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety of CEND-1 mesured by AEs, SAEs and treatment related adverse events.Time frame: 12 month
- Preliminary efficacy of CEND-1 mesured by ORR, DOR, DCR, OS, PFS ect.Time frame: 12 month
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chinese PLA General Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.